ANTARES PHARMA INC's ticker is ATRS and the CUSIP is 036642106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $14,143,000 | +18.6% | 3,449,457 | +3.2% | 0.00% | 0.0% |
| Q4 2021 | $11,928,000 | -5.4% | 3,341,190 | -3.5% | 0.00% | 0.0% |
| Q3 2021 | $12,608,000 | -16.2% | 3,463,675 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $15,046,000 | -22.3% | 3,450,854 | -26.7% | 0.00% | 0.0% |
| Q1 2021 | $19,362,000 | +18.8% | 4,710,985 | +15.4% | 0.00% | 0.0% |
| Q4 2020 | $16,294,000 | +44.5% | 4,083,650 | -2.2% | 0.00% | 0.0% |
| Q3 2020 | $11,277,000 | -10.5% | 4,176,821 | -8.8% | 0.00% | 0.0% |
| Q2 2020 | $12,599,000 | +37.1% | 4,581,279 | +17.7% | 0.00% | 0.0% |
| Q1 2020 | $9,188,000 | -52.3% | 3,893,367 | -5.0% | 0.00% | 0.0% |
| Q4 2019 | $19,269,000 | +44.6% | 4,099,790 | +2.9% | 0.00% | 0.0% |
| Q3 2019 | $13,330,000 | -1.1% | 3,984,965 | -2.7% | 0.00% | 0.0% |
| Q2 2019 | $13,472,000 | +24.1% | 4,094,721 | +14.3% | 0.00% | 0.0% |
| Q1 2019 | $10,857,000 | -3.4% | 3,583,220 | -13.3% | 0.00% | 0.0% |
| Q4 2018 | $11,237,000 | -10.1% | 4,131,348 | +11.0% | 0.00% | 0.0% |
| Q3 2018 | $12,502,000 | +93.7% | 3,721,300 | +48.7% | 0.00% | 0.0% |
| Q2 2018 | $6,454,000 | +16.2% | 2,502,062 | -0.9% | 0.00% | – |
| Q1 2018 | $5,555,000 | +14.0% | 2,524,844 | +3.1% | 0.00% | – |
| Q4 2017 | $4,873,000 | -43.0% | 2,449,128 | -7.1% | 0.00% | -100.0% |
| Q3 2017 | $8,544,000 | +30.8% | 2,636,856 | +30.0% | 0.00% | 0.0% |
| Q2 2017 | $6,530,000 | +3069.9% | 2,027,650 | +2682.1% | 0.00% | – |
| Q1 2017 | $206,000 | +21.2% | 72,881 | 0.0% | 0.00% | – |
| Q4 2016 | $170,000 | +31.8% | 72,881 | -4.3% | 0.00% | – |
| Q3 2016 | $129,000 | +61.2% | 76,181 | 0.0% | 0.00% | – |
| Q2 2016 | $80,000 | -95.5% | 76,181 | -96.3% | 0.00% | – |
| Q1 2016 | $1,794,000 | -28.6% | 2,062,189 | -0.7% | 0.00% | – |
| Q4 2015 | $2,513,000 | -51.4% | 2,076,958 | +8.8% | 0.00% | -100.0% |
| Q1 2015 | $5,172,000 | +5.5% | 1,908,905 | +0.0% | 0.00% | – |
| Q4 2014 | $4,902,000 | +42.0% | 1,908,147 | +1.2% | 0.00% | – |
| Q3 2014 | $3,451,000 | -35.5% | 1,884,903 | -5.9% | 0.00% | -100.0% |
| Q2 2014 | $5,352,000 | -23.7% | 2,003,165 | -0.0% | 0.00% | 0.0% |
| Q1 2014 | $7,012,000 | -55.8% | 2,003,302 | -47.4% | 0.00% | 0.0% |
| Q4 2013 | $15,853,000 | +99.9% | 3,809,837 | +95.0% | 0.00% | 0.0% |
| Q3 2013 | $7,931,000 | +1.5% | 1,953,359 | +4.1% | 0.00% | 0.0% |
| Q2 2013 | $7,810,000 | – | 1,877,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sargent Investment Group, LLC | 4,598,329 | $10,852,000 | 4.99% |
| Soleus Capital Management, L.P. | 864,100 | $2,039,000 | 2.37% |
| Healthcare Value Capital, LLC | 500,000 | $1,180,000 | 1.98% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,227,114 | $2,896,000 | 0.86% |
| PERKINS CAPITAL MANAGEMENT INC | 232,166 | $548,000 | 0.66% |
| Stonepine Capital Management, LLC | 151,189 | $357,000 | 0.38% |
| Zebra Capital Management LLC | 84,963 | $200,000 | 0.32% |
| Intrinsic Edge Capital Management LLC | 1,000,000 | $2,360,000 | 0.31% |
| Alambic Investment Management, L.P. | 46,069 | $109,000 | 0.26% |
| OBERWEIS ASSET MANAGEMENT INC/ | 200,600 | $473,000 | 0.26% |